Clinical Trials
13 trialsNCT03334617 2025-10-27
HUDSON
AstraZeneca
Phase 2 Active not recruiting
NCT02889900 2022-03-08
CONCERTO
AstraZeneca
Phase 2 Completed
NCT00384176 2017-04-14
HORIZON III
AstraZeneca
Phase 2/3 Completed
NCT00423332 2017-02-02
Cediranib (AZD2171, RECENTINā¢) in Metastatic or Recurrent Renal Cell Carcinoma
AstraZeneca
Phase 2 Completed
NCT00399035 2016-12-28
HORIZON II
AstraZeneca
Phase 3 Completed
NCT00777153 2016-12-28
REGAL
AstraZeneca
Phase 3 Completed
NCT00454805 2016-08-03
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.
AstraZeneca
Phase 2 Completed
NCT00494221 2014-03-27
A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX
AstraZeneca
Phase 1/2 Completed
NCT00243347 2013-10-17
The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer
AstraZeneca
Phase 1 Completed
NCT00306891 2012-11-01
Effect of Food Upon Pharmacokinetics of Single Oral Dose of Cediranib (AZD2171, Recentinā¢)
AstraZeneca
Phase 2 Completed
NCT00278889 2012-10-24
HORIZON I
AstraZeneca
Phase 2 Completed
NCT00264004 2012-08-29
Study to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid Tumours
AstraZeneca
Phase 2 Completed
NCT00385203 2012-07-16
The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).
AstraZeneca
Phase 2 Completed